small cell lung carcinoma

small cell lung carcinoma
Nephron · CC BY-SA 3.0 · source
Name	Small cell lung carcinoma
Field	Oncology, Pulmonology, Pathology
Symptoms	Cough, hemoptysis, dyspnea, weight loss
Onset	Adults, commonly older smokers
Risks	Tobacco smoking, radon, asbestos
Diagnosis	Imaging, biopsy, immunohistochemistry
Treatment	Chemotherapy, radiotherapy, immunotherapy, surgery (rare)
Prognosis	Poor; often advanced at presentation

small cell lung carcinoma

Small cell lung carcinoma is an aggressive neuroendocrine malignancy of the lung characterized by rapid growth, early metastasis, and frequent paraneoplastic syndromes. Clinically it presents with central airway lesions and systemic manifestations; management commonly involves combined modality therapy with chemotherapy and radiotherapy. Historical advances in systemic therapy and staging have been influenced by institutions and trials from centers such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Royal Marsden Hospital, and groups like the National Cancer Institute and the European Society for Medical Oncology.

Signs and symptoms

Patients often present with respiratory complaints such as cough, hemoptysis, and dyspnea; these signs are frequently reported at tertiary centers like Mayo Clinic and Johns Hopkins Hospital. Constitutional symptoms including weight loss and fatigue prompt referral to oncologists at institutions such as Dana-Farber Cancer Institute and UCL Hospitals. Rapidly progressive neurologic paraneoplastic features such as Lambert–Eaton myasthenic syndrome may lead to consultations involving specialists from Charité – Universitätsmedizin Berlin and Karolinska University Hospital. Superior vena cava syndrome and pleural effusions are acute presentations managed in settings like Cleveland Clinic and Guy's and St Thomas' NHS Foundation Trust.

Causes and risk factors

The dominant risk factor is exposure to tobacco smoke, a causal link established by epidemiologists at agencies including the World Health Organization and the Centers for Disease Control and Prevention. Occupational exposures such as asbestos and radon contribute to risk profiles studied by researchers at Harvard School of Public Health and Imperial College London. Genetic predisposition and genomic instability investigated at laboratories affiliated with Broad Institute and Wellcome Trust Sanger Institute may modulate susceptibility. Public health policies from institutions like the Royal College of Physicians and legislative actions in parliaments such as the United Kingdom Parliament and United States Congress have influenced population-level smoking prevalence.

Pathophysiology and classification

At the cellular level the tumor arises from neuroendocrine cells of the bronchial epithelium; molecular characterization has been advanced by consortia including The Cancer Genome Atlas and research groups at Cold Spring Harbor Laboratory and Institut Pasteur. Histologically it shows small cells with scant cytoplasm and high mitotic counts, a pattern categorized in classification systems promulgated by the World Health Organization and pathology departments at Mayo Clinic and Guy's and St Thomas' NHS Foundation Trust. Subtypes and molecular phenotypes have been delineated in publications from centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, informing targeted and immunotherapeutic approaches developed at institutions like University of California, San Francisco and Vanderbilt University Medical Center.

Diagnosis

Diagnosis relies on imaging modalities such as chest radiography and computed tomography performed in radiology departments at Royal Brompton Hospital and Mount Sinai Hospital. Positron emission tomography and brain MRI from centers like Karolinska University Hospital and University College London Hospitals assist staging. Tissue diagnosis via bronchoscopic or transthoracic biopsy with immunohistochemistry (markers validated in labs at Johns Hopkins Hospital and Mayo Clinic) confirms the neuroendocrine phenotype. Multidisciplinary tumor boards at comprehensive cancer centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute integrate pathology, radiology, and medical oncology input.

Staging and prognosis

Staging historically used a two-stage system (limited vs extensive) advocated by cooperative groups like the Veterans Administration Lung Study Group, while contemporary practice often applies TNM staging from the Union for International Cancer Control and the American Joint Committee on Cancer. Prognosis is guarded; outcomes reported in trials from National Institutes of Health and large cancer centers show median survival measured in months for extensive disease and improved but limited survival for limited-stage disease treated at centers such as Princess Margaret Cancer Centre. Prognostic factors analyzed by researchers at Fred Hutchinson Cancer Research Center and Peter MacCallum Cancer Centre include performance status, stage, and biochemical markers.

Treatment

Standard systemic therapy employs platinum-based chemotherapy regimens established through randomized trials coordinated by groups such as the Southwest Oncology Group and the European Organisation for Research and Treatment of Cancer. Concurrent thoracic radiotherapy for limited-stage disease is informed by studies from Royal Marsden Hospital and MD Anderson Cancer Center. Prophylactic cranial irradiation to reduce brain metastases has been evaluated in trials reported by the European Society for Medical Oncology and the American Society of Clinical Oncology. Recent advances incorporate immune checkpoint inhibitors developed by pharmaceutical collaborations with institutions like Genentech and AstraZeneca and evaluated in multicenter trials involving Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Surgical resection is uncommon but performed in select cases at centers such as Mayo Clinic and UCLA Health.

Epidemiology and prevention

Incidence and mortality trends have been tracked by registries including the Surveillance, Epidemiology, and End Results Program and the United Kingdom National Cancer Registration and Analysis Service. Global burden estimates from the World Health Organization indicate higher incidence in populations with elevated smoking prevalence; tobacco control measures advocated by the World Health Organization Framework Convention on Tobacco Control and implemented by governments such as United States and United Kingdom have reduced rates in some regions. Screening strategies influenced by trials from National Lung Screening Trial investigators and policy bodies like the U.S. Preventive Services Task Force aim to detect lung cancers earlier in high-risk cohorts identified by public health agencies including Centers for Disease Control and Prevention.

Category:Lung cancer